Valion Bio
VBIO
5 hedge funds and large institutions have $83.8K invested in Valion Bio in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
0.02% more ownership
Funds ownership: 0.25% → 0.27% (+0.02%)
25% less capital invested
Capital invested by funds: $112K → $83.8K (-$28.2K)
29% less funds holding
Funds holding: 7 → 5 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.15K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.33K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$391 |
| 2 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$90 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $60K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $16K | +$2.33K | +101 | +15% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $7.7K | +$5.15K | +223 | +160% |
|
4
Osaic Holdings
Scottsdale,
Arizona
| $182 | – | – | – |
|
5
Wells Fargo
San Francisco,
California
| $14 | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$391 | -13 | Closed |
|
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$90 | -3 | Closed |
|
VBIO Hedge Fund Activity: Q1 2024 in Review
5 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q1 2024, worth a combined $83.8K — down 25% from $112K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of VBIO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 2 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.15K. The largest seller was UBS Group, exiting entirely with an estimated $391 sold.
- 5 institutional investors held Valion Bio (VBIO) as of Q1 2024, down from 7 in Q4 2023.
- Funds reported $83.8K of Valion Bio stock for Q1 2024, down 25% quarter-over-quarter.
- 0 funds opened new Valion Bio positions in Q1 2024 and 2 closed out, a net change of -2 holders.
- The largest Valion Bio buyer in Q1 2024 was Tower Research Capital (TRC), an estimated $5.15K added.
- The largest Valion Bio seller in Q1 2024 was UBS Group, an estimated $391 sold.
Based on aggregated 13F filings for Q1 2024.